🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

13 recruiting trials

for Severe Hepatic Impairment

A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234 NCT07546760Phase 14 sites📍 Chandler📍 Rialto📍 Miami Lakes AstraZeneca · Tests: AZD6234, AZD9550 Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment NCT07036133Phase 14 sites📍 Cerritos📍 Chicago📍 Detroit Acrotech Biopharma Inc. · Tests: Pralatrexate Injection A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers. NCT07401862Phase 13 sites📍 Orlando📍 San Antonio📍 Kistarcsa Eli Lilly and Company · Tests: LY3841136 Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants NCT07250633Phase 13 sites📍 Chandler📍 Orlando📍 San Antonio Institut de Recherches Internationales Servier (I.R.I.S.) · Tests: Vorasidenib 20mg Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment NCT06740799Phase 13 sites📍 Miami📍 Miami📍 St. Petersburg Daiichi Sankyo · Tests: Quizartinib Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment NCT07422610Phase 110 sites📍 Bordeaux📍 Saint-Herblain📍 Milan Novartis Pharmaceuticals · Tests: pelabresib Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations NCT07654855n/a6 sites📍 Los Angeles📍 Vancouver📍 Beijing AstraZeneca · Tests: None ( observational study ) A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment NCT07165002Phase 13 sites📍 Kistarcsa📍 Auckland📍 Bratislava Eli Lilly and Company · Tests: LY3537031 A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function NCT07231991Phase 14 sites📍 Miami📍 Miami Lakes📍 Orlando Pfizer · Tests: vepdegestrant A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine NCT06682988Phase 252 sites📍 Sarasota📍 Edgewood📍 Lexington AbbVie · Tests: Mirvetuximab Soravtansine Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment NCT04953910Phase 122 sites📍 Houston📍 Yerevan📍 Yerevan Taiho Oncology, Inc. · Tests: ASTX727 A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment NCT07559474Phase 14 sites📍 Chandler📍 Orlando📍 San Antonio Incyte Corporation · Tests: INCB123667 A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems NCT07023354Phase 14 sites📍 Rialto📍 Orlando📍 Houston Boehringer Ingelheim · Tests: BI 1291583
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy